ArticleMediators of inflammation2017
The Clinical Significance of Increased Serum Proinflammatory Cytokines, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Patients with Hidradenitis Suppurativa.
Article in Mediators of inflammation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Management of hidradenitis suppurativa in the inpatient setting: a clinical guide.Archives of dermatological research · 2025Guideline
- A state-of-the-art systematic review of cancer in hidradenitis suppurativa.Annals of medicine · 2024Pooled it
- Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa: A Systematic Review.JAMA dermatology · 2022Pooled it
- Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa.International journal of molecular sciences · 2020Pooled it
- A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa.F1000Research · 2018Pooled it
- Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model.Frontiers in immunology · 2018Pooled it
- Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase 2 Randomized Clinical Trial.JAMA dermatology · 2026Trial
- Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies.International journal of dermatology · 2026Trial
- Modulation of Disease-Associated Pathways in Hidradenitis Suppurativa by the Janus Kinase 1 Inhibitor Povorcitinib: Transcriptomic and Proteomic Analyses of Two Phase 2 Studies.International journal of molecular sciences · 2023Trial
- IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study.Experimental dermatology · 2022Trial
- Decoding Inflammation in Hidradenitis Suppurativa: Serum Cytokines as Biomarkers of Disease Severity and Treatment Outcome-Systematic Review.Journal of clinical medicine · 2026Review
- Article
- Laboratory Parameters Can Serve as Objective Auxiliary Tools for Assessing Disease Severity in Hidradenitis Suppurativa: A 5-Year Period Single-Center Retrospective Study.Clinical, cosmetic and investigational dermatology · 2026Article
- Immunohistochemical Expression of Haptoglobin in Skin Lesions of Hidradenitis Suppurativa.Life (Basel, Switzerland) · 2025Article
- Systemic inflammation correlates with depression and lower quality of life in patients with hidradenitis suppurativa independent of disease severity.Archives of dermatological research · 2025Observational
- Evaluation of eating behaviors in patients with hidradenitis suppurativa: A case-control study.Archives of dermatological research · 2025Article
- Hidradenitis Suppurativa Is Associated with an Increased Risk of Adverse Cardiac Events and All-Cause Mortality.Journal of clinical medicine · 2025Article
- C-Reactive Protein and Response to Adalimumab in Patients With Hidradenitis Suppurativa: A Post Hoc Analysis of 2 Randomized Clinical Trials.JAMA dermatology · 2025Article
- Clinical and laboratory characteristics of hidradenitis suppurativa in a Chinese cohort: a retrospective analysis of 197 cases.Frontiers in medicine · 2025Article
- Interplay between Pro-inflammatory Mediators and Oxidative Stressinvolved Recurrent Chronic Heart Failure in Elderly Patients with Coronary Stents.Current medicinal chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess inflammatory serum markers including serum proinflammatory cytokines, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) according to the clinical inflammatory activity of patients with hidradenitis suppurativa (HS). PATIENTS AND
methodsSeventy-four patients with HS were studied based on the Hidradenitis Suppurativa-Physician Global Assessment (HS-PGA) score and Hurley staging system. Proinflammatory cytokines were measured using a multiplex cytokine assay. Twenty-two healthy volunteers were recruited.
resultsSerum interleukin- (IL-) 6, IL-23, soluble tumour necrosis factor alpha (TNF-
conclusionsSerum proinflammatory cytokines, CRP, and ESR are increased in relation to the clinical inflammatory activity of patients with HS compared with healthy controls. Serum IL-6, CRP, and ESR are effective biomarkers for evaluating the severity of HS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.